<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Treatment of &lt;em&gt;Clostridioides difficile&lt;/em&gt; infection in children</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Treatment of <em>Clostridioides difficile</em> infection in children</h1>
<div class="graphic"><div class="figure"><div class="ttl">Treatment of <em>Clostridioides difficile</em> infection in children</div><div class="cntnt"><table cellspacing="0"><colgroup width="25%"></colgroup><colgroup width="75%"></colgroup> <tbody> <tr> <td class="subtitle1">Clinical features</td> <td class="subtitle1">Suggested treatment</td> </tr> <tr> <td class="subtitle2_left" colspan="2">First episode</td> </tr> <tr> <td class="indent1">Mild or moderate</td> <td> <ul> <li>Vancomycin 40 mg/kg per day orally divided in 4 doses (maximum dose: 125 mg) for 10 days, <strong>or</strong></li> <li>Metronidazole 30 mg/kg per day orally divided in 4 doses (maximum dose: 500 mg) for 10 days, <strong>or</strong></li> <li>Fidaxomicin, dosed according to body weight: <ul> <li>4 to &lt;7 kg (oral suspension): 80 mg orally twice daily for 10 days</li> <li>7 to &lt;9 kg (oral suspension): 120 mg orally twice daily for 10 days</li> <li>9 to &lt;12.5 kg (oral suspension): 160 mg orally twice daily for 10 days</li> <li>≥12.5 kg (oral suspension): 200 mg orally twice daily for 10 days</li> </ul> </li> </ul> </td> </tr> <tr> <td class="indent1">Severe*</td> <td> <ul> <li>Vancomycin 40 mg/kg per day orally divided in 4 doses (maximum dose: 125 mg) for 10 days</li> </ul> </td> </tr> <tr> <td class="indent1">Fulminant<sup>¶</sup></td> <td> <ul> <li>Metronidazole 30 mg/kg per day IV divided in 3 doses (maximum dose: 500 mg), <strong>plus</strong></li> <li>Vancomycin 40 mg/kg per day orally divided in 4 doses (maximum dose: 500 mg) until clinical improvement and then (if applicable) decrease the maximum dose to 125 mg to complete 10 days</li> </ul> </td> </tr> <tr> <td class="indent1">Fulminant<sup>¶</sup> disease and ileus</td> <td> <ul> <li>Metronidazole 30 mg/kg per day IV divided in 3 doses (maximum dose: 500 mg), <strong>plus</strong></li> <li>Vancomycin 10 mg/kg per dose in normal saline (maximum dose: 500 mg in 100 mL normal saline) administered by retention enema 4 times per day<sup>Δ</sup>; the volume of solution varies with age: <ul> <li>1 through 4 years: 50 mL</li> <li>5 through 11 years: 75 mL</li> <li>≥12 years: 100 mL</li> </ul> </li> </ul> </td> </tr> <tr> <td class="subtitle2_left" colspan="2">Recurrent episodes</td> </tr> <tr> <td class="indent1">First recurrence, mild or moderate</td> <td> <ul> <li>Repeat regimen used for first episode</li> </ul> </td> </tr> <tr> <td class="indent1">Subsequent recurrence, mild or moderate</td> <td><strong>Either</strong> of the following: <ul class="decimal_heading"> <li>Pulsed-tapered vancomycin (maximum dose: 125 mg): <ul> <li>10 mg/kg orally 4 times daily for 10 to 14 days, followed by</li> <li>10 mg/kg orally twice daily for 7 days, followed by</li> <li>10 mg/kg orally once daily for 7 days, followed by</li> <li>10 mg/kg orally every other day for 7 days, followed by</li> <li>10 mg/kg orally every 3 days for 2 to 8 weeks</li> </ul> </li> <li>Fidaxomicin, dosed according to weight: <ul> <li>4 to &lt;7 kg (oral suspension): 80 mg orally twice daily for 10 days</li> <li>7 to &lt;9 kg (oral suspension): 120 mg orally twice daily for 10 days</li> <li>9 to &lt;12.5 kg (oral suspension): 160 mg orally twice daily for 10 days</li> <li>≥12.5 kg (oral suspension or tablets): 200 mg orally twice daily for 10 days</li> </ul> </li> </ul> </td> </tr> </tbody></table></div><div class="graphic_lgnd">This table is meant to be used in conjunction with the UpToDate topic on treatment of <em>C. difficile</em> infection in children.</div><div class="graphic_footnotes"><p>IV: intravenous.</p>
<p>* There is no consensus definition of severe <em>C. difficile</em> infection in children. Determination of disease severity should be guided by clinician judgment. We use the following criteria to define severe disease: Fever, profuse diarrhea, abdominal pain and tenderness, abdominal distention, white blood cell count &gt;15,000 cells/microL, elevated age-adjusted creatinine level, serum albumin &lt;2.5 g/dL (25 g/L), and pseudomembranous colitis.</p>
<p>¶ Fulminant disease is characterized by hypotension, shock, ileus, or toxic megacolon.</p>
Δ The optimal dose and volume for rectal vancomycin has not been established for children or adults. Dose and volume adjustments may be required depending upon individual circumstances, extent of colonic disease, and patient weight. Caution is required because perforation is possible with rectal installation of vancomycin.</div><div class="graphic_reference">Adapted from: McDonald LC, Gerding DN, Johnson S, et al. Clinical practice guidelines for Clostridium difficile infection in adults and children: 2017 update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). Clin Infect Dis 2018.</div><div id="graphicVersion">Graphic 117235 Version 7.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
